DUHE Group

Inner Mongolia Duhe Chuangyan Technology Development Co., Ltd. (“Duhe”) is a biotech company pioneering scalable, cost-efficient synthesis technologies for α-amanitin and other cyclic peptide toxins used as payloads in Antibody-Drug Conjugates (ADCs). Founded in 2019, Duhe has developed proprietary methods that significantly reduce synthesis steps, increase purity, and improve overall production economics. These innovations address major bottlenecks in the ADC field, particularly the limited supply and high cost of α-amanitin. In addition to toxin payloads, Duhe also synthesizes unnatural amino acids, peptide drugs, and other complex molecules for pharmaceutical applications. Backed by Chinese investors, the company employs 20 staff and is now actively engaging global biopharma partners to commercialize its platform.